Soligenix Enhances Medical Advisory Board for Clinical Advancement
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has made significant updates to its United States Medical Advisory Board (MAB) for Cutaneous T-Cell Lymphoma (CTCL). This update aims to enhance the medical and clinical guidance provided as the company progresses with the Phase 3 clinical development of HyBryte™ (synthetic hypericin) for CTCL, a rare and often challenging form of non-Hodgkin's lymphoma (NHL).
Objective of the Medical Advisory Board
The MAB comprises leading dermatologic and oncologic experts with vast experience in CTCL. Their ongoing advisory role is crucial for the FLASH2 Phase 3 pivotal clinical study aimed at refining essential development activities, including regulatory interactions with health authorities worldwide. Recent updates to the MAB include the addition of key opinion leaders, all of whom have served as principal investigators in the HyBryte™ clinical program. These specialists will contribute valuable insights into the needs of the CTCL patient community.
Leadership Insights
Christopher J. Schaber, PhD, President and CEO of Soligenix, expressed excitement about the new members of the MAB, stating, "We are pleased to be able to attract such esteemed and enthusiastic professionals to participate as members of our Medical Advisory Board. Many of the MAB members have experience treating patients with HyBryte™ and have been invaluable to the program. We are excited to continue to work with them to facilitate the advancement of HyBryte™ to commercialization worldwide." This cooperative endeavor aspires to develop clinical strategies and explore potential expansions into home-use applications while addressing health economics and reimbursement.
Key Members of the Medical Advisory Board
Among the notable members of the MAB are:
Dr. Jennifer DeSimone, MD
Dr. DeSimone is a prominent Associate Professor of Dermatology at a leading institution. She leads a high-volume cutaneous lymphoma subspecialty clinic, treating a significant number of patients. Her extensive research includes principal investigator roles in multiple trials and contributions to over 35 peer-reviewed publications.
Dr. Youn Kim, MD
Dr. Kim occupies a leadership position in cutaneous lymphoma research at a prestigious medical school. With a notable track record of over 350 publications, her commitment to advancing CTCL treatment has made her an invaluable asset to the MAB.
Dr. Aaron Mangold, MD
Specializing in complex medical dermatology, Dr. Mangold plays a pivotal role in the clinical trial operations at the Mayo Clinic. His extensive publication history reflects a dedication to innovative research in CTCL.
Dr. Brian Poligone, MD, PhD - Chair
As the Chair of the MAB, Dr. Poligone leads research in skin lymphoma at a respected medical group. With significant expertise in both clinical and scientific domains, he stands out for his contributions to advancing HyBryte™ therapy.
The Importance of HyBryte™
HyBryte™, also known as SGX301, represents a pioneering photodynamic therapy that uses safe visible light to activate synthetic hypericin, targeting malignant T-cells on skin lesions. This novel therapeutic approach is designed to minimize the risks associated with traditional DNA-damaging drugs, offering a safer alternative for treating CTCL.
The product has received recognition from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) due to its potential benefits and unique safety profile. The marked improvement seen in patient responses during clinical trials emphasizes HyBryte™'s promising therapeutic landscape.
Future Developments in CTCL Treatments
Following initial clinical studies demonstrating significant efficacy, Soligenix is in the process of conducting the second Phase 3 study, FLASH2, which aims to further validate HyBryte™ as a preferred treatment for early-stage CTCL. This study will involve a randomized, double-blind, placebo-controlled design, a method previously acknowledged for producing reliable results.
Clinical Insights and Experiences
The ongoing engagement with the CTCL community and robust feedback from the advisory board members are expected to enhance patient enrollment and streamline the investigational process for the ongoing trials. Successful completion of this study will support regulatory pathways toward commercialization.
Community Impact and Patient Support
CTCL affects a small fraction of the population; however, its impact is profound. Soligenix is dedicated to addressing the unmet medical needs of affected individuals. They aim to develop HyBryte™ as a safe and effective treatment that can improve the quality of life for those battling this challenging disease.
Enhancing Patient Outcomes
Through strategic collaborations and continued innovations, Soligenix is paving the way for advancements in CTCL therapies. Their emphasis on safety, efficacy, and availability of treatments reflects a broader commitment to enhancing patient outcomes and supporting a community in need.
Frequently Asked Questions
What is the significance of the Medical Advisory Board for Soligenix?
The Medical Advisory Board provides expert guidance and insights to enhance the development and commercialization strategies for HyBryte™, helping address patient needs effectively.
How does HyBryte™ work?
HyBryte™ is a photodynamic therapy that activates synthetic hypericin under visible light, targeting malignant T-cells while minimizing risks associated with traditional treatments.
What are the key studies supporting HyBryte™?
Previous clinical studies, including the FLASH trial, demonstrated significant improvements in patient responses, leading to ongoing Phase 3 trials for further validation.
Who are the new members of the MAB?
The updated MAB includes distinguished experts in dermatology and oncology, contributing their vast experience and insights into CTCL treatment.
What is the future outlook for CTCL treatments from Soligenix?
With a focus on ongoing clinical trials and regulatory engagement, Soligenix aims to establish HyBryte™ as a preferred treatment option for patients with CTCL.
